TSHA
Taysha Gene Therapies, Inc.NASDAQHealthcare$4.37+1.39%ClosedMarket Cap: $1.09B
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
6.02
P/S
119.03
EV/EBITDA
-7.96
DCF Value
$0.59
FCF Yield
-8.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
94.0%
Operating Margin
-1130.6%
Net Margin
-1115.3%
ROE
-56.6%
ROA
-31.7%
ROIC
-34.9%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $5.5M | 94.5% | $-28.3M | $-27.9M | $-0.08 | — |
| FY 2025 | $9.8M | 88.3% | $-110.5M | $-109.0M | $-0.34 | — |
| Q3 2025 | $0.00 | -Infinity% | $-34.0M | $-32.7M | $-0.09 | — |
| Q2 2025 | $2.0M | 100.0% | $-26.8M | $-26.9M | $-0.09 | — |
| Q1 2025 | $2.3M | 100.0% | $-21.4M | $-21.5M | $-0.08 | — |
| Q4 2024 | $2.0M | 100.0% | $-19.9M | $-18.8M | $-0.09 | — |
| FY 2024 | $8.3M | 100.0% | $-91.5M | $-89.3M | $-0.36 | — |
| Q3 2024 | $1.8M | 100.0% | $-25.9M | $-25.5M | $-0.10 | — |
| Q2 2024 | $1.1M | 100.0% | $-21.3M | $-20.9M | $-0.09 | — |
| Q1 2024 | $3.4M | 100.0% | $-24.3M | $-24.1M | $-0.10 | — |
| Q4 2023 | $3.6M | 100.0% | $-16.2M | $47.7M | $0.26 | — |
| FY 2023 | $15.5M | 100.0% | $-72.4M | $-111.6M | $-0.96 | — |